Research

Is the backbone of Lilly.

Lilly Research Laboratories (LRL) discovers and develops high-quality innovative medicines that help people live longer, healthier, happier lives. This is done in a reliable and cost-effective manner and in an atmosphere of optimism, teamwork, quality and compliance.

Our investment in research and development has been sustained at a high level over many years and has resulted in one of the most prolific pipelines in the industry, with more than 60 potential medicines currently in development.

“Research is the Heart of the Business, the Soul of the Enterprise."

Mr. Eli Lilly, Grandson of Lilly’s founder Colonel Eli Lilly

With research and development facilities located in eight countries and clinical research conducted in more than 55 countries Lilly invests above average % of sales into R&D – circa 20%. Lilly’s annual investment in R&D in Europe doubled to over €450 million over the last decade.

Lilly supports the Innovative Medicines Initiative the largest private-public partnership in Life Science R&D and actively participates in some 19 projects for diabetes, neuroscience and oncology, investing more than €20 million